Novo Nordisk A/S Dividend History (NVO)
🤑 Novo Nordisk A/S has distributed a total of 31 dividends from 2003 to 2024
📉 During this 21 period their dividend has seen a -1.14% decrease in the payout amount
About Novo Nordisk A/S
Novo Nordisk A/S is a renowned global healthcare company anchored in Denmark, primarily known for its leadership in diabetes care. Founded in 1923 through the merger of two Danish companies, Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium, the company has grown into one of the world’s largest producers of insulin. Novo Nordisk is dedicated to driving change in diabetes treatment with a wide spectrum of products ranging from insulin medications to systems for diabetes management. Besides diabetes care, the company is actively involved in research and development for other serious chronic conditions such as obesity, hemophilia, and growth disorders. With over 100 years in operation, Novo Nordisk is a key player in global health and innovation in the pharmaceutical industry. The company continues to thrive with significant revenues, reflecting its impact and presence in over 170 countries worldwide.
Eli Lilly's weight loss drug Zepabound outperformed Novo Nordisk's Wegovy in a clinical trial, setting the stage for Lilly to gain market share in the growing GLP-1 weight loss drug market.
Investing.com · Published on Thu Dec 05 2024Amgen's weight loss drug candidate MariTide faces competition from Eli Lilly's Zepbound and Novo Nordisk's Wegovy. While MariTide has a convenience advantage with monthly dosing, its efficacy and tolerability are not significantly better than the incumbents. Amgen's stock is still worth buying on the dip as MariTide could potentially fill a niche for more tolerable and convenient weight loss solutions.
The Motley Fool · Published on Sat Nov 30 2024Novo Nordisk, a Danish pharmaceutical company, has seen strong growth in recent years due to its GLP-1 drugs. While the company faces increasing competition, its pipeline of obesity and diabetes treatments, including the promising semaglutide, suggests continued growth potential. However, the stock's valuation and the competitive landscape warrant caution.
The Motley Fool · Published on Fri Nov 29 2024Previous Payouts (31)
The most recent dividend Novo Nordisk A/S paid out was on August 26, 2024 (101 days ago) for $0.5169016 per share
Pay Date | Amount |
---|---|
August 26, 2024 | $0.5169016 |
April 2, 2024 | $0.9293348 |
August 29, 2023 | $0.8763389 |
April 4, 2023 | $1.1805812 |
August 23, 2022 | $0.5777452 |
April 5, 2022 | $1.022423 |
August 25, 2021 | $0.5502889 |
April 7, 2021 | $0.922122 |
August 25, 2020 | $0.5177774 |
April 7, 2020 | $0.7826048 |
August 27, 2019 | $0.449438 |
April 2, 2019 | $0.777006 |
August 28, 2018 | $0.462327 |
April 3, 2018 | $0.805982 |
August 29, 2017 | $0.473821 |
April 4, 2017 | $0.670368 |
August 23, 2016 | $0.453459 |
March 30, 2016 | $0.958141 |
March 31, 2015 | $0.72998 |
April 2, 2014 | $0.830304 |
April 2, 2013 | $3.10179 |
April 3, 2012 | $2.509455 |
April 5, 2011 | $1.885974 |
April 7, 2010 | $1.359188 |
March 31, 2009 | $1.085462 |
March 25, 2008 | $0.942309 |
March 20, 2007 | $1.238582 |
March 21, 2006 | $0.960768 |
March 22, 2005 | $0.85729 |
March 29, 2004 | $0.72356 |
April 7, 2003 | $0.52287 |
Dividend data last updated Thu, 05 Dec 2024 12:09:10 GMT UTC